Genosco is a clinical-stage biotech pursuing discovery and development of novel small-molecule drugs for patients with unmet medical needs. Our proprietary G-SMART™ platform enables discovery and optimization based on rare sequences in protein kinases that can be targeted to develop a highly selective compound. This innovative approach has enabled us to build a strong portfolio of multiple independent and partnered pipelines. Our most advanced pipeline, Lazertinib, is currently undergoing phase 3 global clinical trial by Janssen and is also available in Korea for patients with EGFRm+ non-small cell lung cancer. Robust research and discovery programs are also underway. With a shared mission to enhance people’s lives through innovative science, we are united in developing world-class precision medicine to help people have healthier and longer lives. Our interdisciplinary team consists of scientists with deep expertise in medicinal chemistry, structural & computational drug discovery design, cell biology, pharmacology, and drug metabolism.